Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (3067)	12/2/1997 1:42:00 PM
From: tommysdad	Read Replies (3) of 6136

Yes, the San Diego Union-Tribune article was fairly favorable, but it concentrated on a single individual whose tumor was (apparently) virtually eliminated by Thymitaq. But, the last paragraph noted that not everyone had responded, and the article was actually prompted by IDEC's (another San Diego biotech) recent FDA approval of a cancer drug. The point was Agouron had the first San Diego biotech drug (Viracept) and IDEC had the second {Rituxan (sp?)}. No one was duped here. "Effectiveness" and "response rate" are two very different things. The article stated Thymitaq was very effective in one guy. I too hoped David S. was wrong, but he wasn't.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next